FDA’s requirement for a new cardiovascular outcomes study of Abbott Laboratories Inc.’s Trilipix (fenofibric acid) provides an opportunity to confirm benefit in one patient subgroup in the ACCORD-Lipid trial that showed positive results.
Abbott will conduct a randomized, double-blind, placebo-controlled trial evaluating the effect of Trilipix on the incidence of major CV events...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?